Tokai Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that management will participate in the following upcoming investor conferences:
- Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at the Grand Hyatt in New York City
- William Blair’s 35th Annual Growth Stock Conference on Thursday, June 16, 2016 at the Four Seasons Hotel in Chicago, with a presentation at 8:00 AM CT
A live webcast of the William Blair presentation can be accessed under the “Calendar of Events” page within the “Investors & Media” section of the company’s website at www.tokaipharmaceuticals.com. A replay of the webcast will be archived on the company’s website for 90 days following the date of the presentation.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of current second-generation anti-androgens, while also introducing a unique third mechanism – androgen receptor degradation. Tokai is developing galeterone for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. For more information on the company and galeterone, please visit www.tokaipharmaceuticals.com.
Source: Tokai Pharmaceuticals Inc.
Tokai Pharmaceuticals Inc.
Lee Kalowski, 617-225-4305
Chief Financial Officer
David Pitts/Maeve Conneighton, 212-600-1902
Ten Bridge Communications
Dan Quinn, 781-475-7974